Compare LQDA & FCPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LQDA | FCPT |
|---|---|---|
| Founded | 2004 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.1B | 2.6B |
| IPO Year | 2020 | 2015 |
| Metric | LQDA | FCPT |
|---|---|---|
| Price | $37.80 | $25.40 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 11 | 7 |
| Target Price | ★ $41.00 | $27.71 |
| AVG Volume (30 Days) | ★ 1.1M | 665.6K |
| Earning Date | 05-07-2026 | 04-29-2026 |
| Dividend Yield | N/A | ★ 5.71% |
| EPS Growth | ★ 51.81 | 1.87 |
| EPS | N/A | ★ 1.09 |
| Revenue | $158,320,000.00 | ★ $294,132,000.00 |
| Revenue This Year | $278.87 | $6.66 |
| Revenue Next Year | $57.13 | $8.28 |
| P/E Ratio | ★ N/A | $23.55 |
| Revenue Growth | ★ 1031.18 | 9.72 |
| 52 Week Low | $11.85 | $22.78 |
| 52 Week High | $46.67 | $28.98 |
| Indicator | LQDA | FCPT |
|---|---|---|
| Relative Strength Index (RSI) | 49.78 | 58.99 |
| Support Level | $31.75 | $25.22 |
| Resistance Level | $39.19 | $26.09 |
| Average True Range (ATR) | 2.12 | 0.47 |
| MACD | 0.09 | 0.18 |
| Stochastic Oscillator | 37.52 | 84.09 |
Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also conducting studies on L606, an investigational, liposomal formulation of treprostinil.
Four Corners Property Trust Inc is a real estate investment trust predominantly engaged in the ownership, acquisition and leasing of restaurant and retail properties. The company seeks to grow its portfolio by acquiring additional real estate to lease, on a net basis, for use in the restaurant and retail industries. The firm operates through two segments namely, real estate operations and restaurant operations. The real estate operations segment consists of rental revenues generated by leasing restaurant and retail properties to tenants. The restaurant operations segment is conducted through a taxable REIT subsidiary (TRS) and consists of Kerrow Restaurant Operating Business. The firm generates majority of the revenue from the real estate operations segment.